sipuleucel T
Selected indexed studies
- Sipuleucel-T immunotherapy for castration-resistant prostate cancer. (N Engl J Med, 2010) [PMID:20818862]
- Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. (Future Oncol, 2018) [PMID:29260582]
- Sipuleucel-T: immunotherapy for advanced prostate cancer. (Open Access J Urol, 2011) [PMID:24198636]
_Worker-drafted node — pending editorial review._
Connections
sipuleucel T is a side effect of
Sources
- Sipuleucel-T immunotherapy for castration-resistant prostate cancer. (2010) pubmed
- Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. (2018) pubmed
- Sipuleucel-T: immunotherapy for advanced prostate cancer. (2011) pubmed
- Sipuleucel-T: in metastatic castration-resistant prostate cancer. (2011) pubmed
- Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. (2012) pubmed
- Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resistant prostate cancer. (2025) pubmed
- Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. (2008) pubmed
- Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer. (2021) pubmed
- Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis. (2016) pubmed
- Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy. (2015) pubmed